Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Executive Summary

Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.

You may also be interested in...



Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes

A legal settlement with BioMarin means that Sarepta doesn't have to worry anymore about the potential to infringe patents related to exon-skipping DMD therapies. Meanwhile, BioMarin gains some compensation for its ill-fated Prosensa buy.

Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel